Blosozumab

布索珠单抗

Report date: 2025/06/24 16:51:51

Base Information

Drug NameBlosozumab
Drug Alias NameBlosozumabum布洛索珠单抗LY-2541546TST002TST002-IgG4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSclerostin inhibitors
TargetsSclerostin
Therapy Area/IndicationsOsteoporosis, PostmenopausalOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkLithuania +[6
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesEli Lilly And Company
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsOsteoporosis

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG